Kymriah is a medicine for treating the following types of blood cancer: • B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells; • Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments. Kymriah is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the body. The blood cancers that Kymriah is used to treat are rare, and Kymriah was designated an ‘orphan medicine’ (a medicine used in rare diseases) for B-cell ALL on 29 April 2014, DLBCL on 14 October 2016 and FL on 19 July 2021. Kymriah contains the active substance tisagenlecleucel (consisting of genetically modified white blood cells).
Therapeutic Indication
### Therapeutic indication Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01XL04
ATC Item
tisagenlecleucel
Pharmacotherapeutic Group
Other antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tisagenlecleucel | N/A | 替沙仑赛注射液 |
EMA Name
Kymriah
Medicine Name
Kymriah
Aliases
N/ANo risk management plan link.
